New Study in Newborns Finds Nellcor™ Pulse Oximetry Technology Provides Faster Stable Oxygen Saturation Readings Than Masimo Pulse Oximeter
- Study Compared the Efficacy and Reliability of Medtronic and Masimo Pulse Oximeters with Electrocardiography (ECG) Monitoring for Newborns
- Nellcor™ Pulse Oximetry Technology Demonstrated Statistically Significant Difference in Time to Deliver a Stable Oxygen Saturation Value and Heart Rate
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the results of an independent, prospective observational study comparing the efficacy and reliability of two pulse oximeters — Nellcor™ Bedside SpO2 Patient Monitoring System and Masimo Radical-7® Pulse CO-Oximeter®, both set at the highest sensitivity ("Neonatal" and "Fast" for Nellcor™ pulse oximetry technology and "Max" for Masimo) — with electrocardiography (ECG) monitoring following the delivery of 60 term newborns by Caesarian section. Pulse oximetry is a simple, noninvasive bedside test that can accurately detect the percentage of blood saturated with oxygen and measure heart rate.
According to the study, a stable signal was obtained from all 60 newborns with the Nellcor pulse oximeter but from only 55 newborns with the Masimo pulse oximeter. Of the 55 newborns with stable signals from both monitors, the mean time to stable signal with the Nellcor pulse oximeter was 15 seconds compared with 27 seconds with the Masimo pulse oximeter. The average difference of 12 seconds between the monitors was statistically significant (P
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.